Naturally occurring antibodies (NAbs):
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer [u.a.]
2012
|
| Schriftenreihe: | Advances in experimental medicine and biology
750 |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Includes bibliographical references and index |
| Beschreibung: | XXI, 267 S. Ill., graph. Darst. |
| ISBN: | 9781461434603 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV040290715 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 120704s2012 ad|| |||| 00||| eng d | ||
| 010 | |a 2012005554 | ||
| 020 | |a 9781461434603 |9 978-1-461-43460-3 | ||
| 035 | |a (OCoLC)795954231 | ||
| 035 | |a (DE-599)GBV685351335 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 082 | 0 | |a 616.07/98 | |
| 245 | 1 | 0 | |a Naturally occurring antibodies (NAbs) |c ed. by Hans U. Lutz |
| 264 | 1 | |a New York, NY |b Springer [u.a.] |c 2012 | |
| 300 | |a XXI, 267 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Advances in experimental medicine and biology |v 750 | |
| 500 | |a Includes bibliographical references and index | ||
| 700 | 1 | |a Lutz, Hans Ulrich |e Sonstige |4 oth | |
| 830 | 0 | |a Advances in experimental medicine and biology |v 750 |w (DE-604)BV000003102 |9 750 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025145906&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025145906 | ||
Datensatz im Suchindex
| _version_ | 1804149304088068096 |
|---|---|
| adam_text | Titel: Naturally occurring antibodies (NAbs)
Autor: Lutz, Hans Ulrich
Jahr: 2012
CONTENTS
SECTION I: NAbs IN TISSUE REPAIR
AND TISSUE HOMEOSTASIS
1. NATURALLY OCCURRING IgM ANTIBODIES
TO OXIDATION-SPECIFIC EPITOPES......................................................2
Christoph J. Binder
Abstract.........................................................................................................................................2
Introduction..................................................................................................................................2
Oxidation-Specific Epitopes as Danger Associated Molecular Patterns .............................3
Oxidation-Specific Epitopes Are Bound by Specific Antibodies..............................................4
Oxidation-Specific Epitopes Are Prominent Targets of IgM NAbs.........................................5
Functional Role of IgM NAbs with Specificity for Oxidation-Epitopes..................................6
Naturally Occurring IgM Antibodies in Atherosclerosis..........................................................9
Naturally Occurring IgM Antibodies as Biomarkers of Cardiovascular Disease................10
Conclusion..................................................................................................................................10
2. NATURALLY OCCURRING AUTOANTIBODIES
TO APOPTOTIC CELLS..............................................................................14
Keith B. Elkon and Gregg J. Silverman
Abstract.......................................................................................................................................14
Introduction................................................................................................................................14
Cell Surface Membrane Changes during Cell Death.............................................................15
Antibodies to Cell Surface Antigens That Become Exposed on Apoptotic Cells..................16
Biological Functions of NAbs to Apoptotic Cells....................................................................19
Regulatory NAbs May Block Development of Inflammatory
Autoimmune Disease.........................................................................................................22
Conclusion: Unanswered Questions and Future Applications..............................................23
3. NATURALLY OCCURRING ANTIBODIES DIRECTED
AGAINST CARBOHYDRATE TUMOR ANTIGENS...............................27
Reinhard Schwartz-Albiez
Abstract.......................................................................................................................................27
Introduction........................................................................................................................—....27
Characterization and Origin of Anti-Carbohydrate Antibodies...........................................28
Tumor-Associated Carbohydrate Antigens as Target Structures
for Anti-Tumor Antibodies................................................................................................31
Mechanisms of Cell Lysis..........................................................................................................36
Protection Mechanisms of Tumor Cells...................................................................................38
Therapeutic Approaches............................................................................................................39
Conclusion and Perspectives.....................................................................................................39
4. NATURALLY OCCURRING ANTIBODIES
AS THERAPEUTICS FOR NEUROLOGIC DISEASE:
CAN HUMAN MONOCLONAL IgMs REPLACE
THE LIMITED RESOURCE IVIG?............................................................44
Arthur E. Warrington, Virginia Van Keulen, Larry R. Pease and Moses Rodriguez
Abstract.......................................................................................................................................44
Introduction...—.....-----„_____...............___...______....._____..___......__.....____....___45
Current Use of IVIG in Neurologic Disease............................................................................45
IVIG to Treat Optic Neuritis.....................................................................................................46
Lessons from NAbs to Promote CNS Remyelination____.......___....___...___.____.__... 47
Human Antibodies That Promote Remyelination...................................................................47
Development of a Recombinant Expression Vector for Human IgMs..................................49
Evidence That the IgM Isotype is Superior to IgG in Repair
of the Nervous System.......................................................................................................50
Ca2+ Signaling is a Common Link in IgMs That Promote Remyelination............................51
Naturally Occurring Autoantibodies in the Treatment of Alzheimer Disease--------..------52
Conclusion..................................................................................................................................53
5. NATURE AND NURTURE OF CATALYTIC ANTIBODIES............................56
Sudhir Paul, Stephanie A. Planque, Yasuhiro Nishiyama, Carl V. Hanson
and Richard J. Massey
Abstract.......................................................................................................................................56
Introduction................................................................................................................................57
Constitutive or Naturally-Occurring Antibodies................................................................58
Beyond Binding: Catalytic Antibodies.....................................................................................60
Promiscuous Catalytic Antibodies............................................................................................62
Catalytic Autoantibodies...........................................................................................................63
Catalytic Antibodies in Defense against Microbes..................................................................65
Catalytic Antibodies as Second Generation Therapeutics.....................................................67
Catalytic and Covalent Vaccination.........................................................................................69
Conclusion..................................................................................................................................72
6. NATURALLY OCCURRING AUTOANTIBODIES
IN MEDIATING CLEARANCE OF SENESCENT
RED BLOOD CELLS.....................................................................................76
Hans U. Lutz
Abstract.......................................................................................................................................76
Introduction to Tissue Homeostasis.........................................................................................76
Means to Clear Senescent Red Blood Cells.............................................................................77
The Specificity of NAbs Involved in Clearance of Senescent
Red Blood Cells..................................................................................................................78
The Fine Specificity of Anti-Band 3 NAbs...............................................................................81
Functional Properties of NAbs and How a Low Affinity IgG NAb,
Like Anti-Band 3, Stimulates Complement Amplification.............................................83
Anti-Band 3 Autoantibodies or Anti-Band 3 NAbs in Anemia..............................................85
What Alterations are Required for Anti-Band 3 NAbs to Bind
to Band 3 Clusters..............................................................................................................86
Conclusion and Outlook............................................................................................................87
7. NATURALLY OCCURRING AUTOANTIBODIES AGAINST
ß-AMYLOID...................................................................................................91
Jan-Philipp Bach and Richard Dodel
Abstract.......................................................................................................................................91
Introduction................................................................................................................................91
Isolation of Anti-Aß NAbs.........................................................................................................92
Origin of Naturally Occurring Autoantibodies.............„........................................................93
Epitope........................................................................................................................................94
Glycosylation..............................................................................................................................94
Assays Used to Detect Autoantibodies against Aß...................................................................95
Metabolism of Anti-Aß NAbs....................................................................................................95
Clinical Studies in Alzheimer Disease......................................................................................95
Conclusion..................................................................................................................................96
8. MULTI-FACETED ROLE OF NATURALLY OCCURRING
AUTOANTIBODIES IN FIGHTING PATHOGENS................................100
Hicham Bouhlal and Srini Kaveri
Abstract.....................................................................................................................................100
Introduction..............................................................................................................................100
NAbs in the Treatment of Bacterial Infections......................................................................101
NAbs in the Control of Viral Infection...................................................................................101
Conclusion................................................................................................................................109
SECTION H: NAbs MODULATING AND REGULATING
CELLS OF THE IMMUNE SYSTEM
9. IMMUNOREGULATION BY NATURALLY OCCURRING
AND DISEASE-ASSOCIATED AUTOANTIBODIES:
BINDING TO CYTOKINES AND THEIR ROLE
IN REGULATION OF T-CELL RESPONSES..........................................116
Claus H. Nielsen and Klaus Bendtzen
Abstract.....................................................................................................................................116
Introduction..............................................................................................................................117
Autoantibodies against Cytokines..........................................................................................117
Immunoregulatory NAbs against Non-Cytokine Self-Antigens..........................................124
Regulation of T-Cell Responses by NAbs and Complement................................................127
Differences between Autoantibodies in Health and Disease.................................................127
Conclusion................................................................................................................................128
10. MODULATION OF DENDRITIC CELLS AND REGULATORY
T CELLS BY NATURALLY OCCURRING ANTIBODIES....................133
Jaap Kwekkeboom
Abstract.....................................................................................................................................133
Introduction..............................................................................................................................133
NAbs and Dendritic Cells........................................................................................................134
NAbs and T Cells.....................................................................................................................139
NAbs and Regulatory T Cells.................................................................................................139
Conclusion................................................................................................................................141
11. CONTROL OF B CELLS EXPRESSING NATURALLY
OCCURRING AUTOANTIBODIES..........................................................145
Jean Louis Pasquali and Thierry Martin
Abstract.....................................................................................................................................145
Introduction..............................................................................................................................145
Structure-Activity Relationships among NAbs.....................................................................146
Regulation of Autoimmunity...................................................................................................148
Conclusion................................................................................................................................154
12. GRANULOCYTE DEATH REGULATION BY NATURALLY
OCCURRING AUTOANTIBODIES..........................................................157
Stephan von Gunten and Hans-Uwe Simon
Abstract.....................................................................................................................................157
Introduction..............................................................................................................................157
Siglecs........................................................................................................................................159
Neutrophil Death Induced by Natural Anti-Siglec-9 Autoantibodies.................................161
CONTENTS ris
Eosinophil Death Induced by Natural Anti-Siglec-8 Autoantibodies:
A Role in Allergic Disease?..............................................................................................164
Similarities and Differences between Granulocyte Death-Inducing
Naturally Occurring Autoantibodies..............................................................................165
Regulation of Granulocyte Death-Inducing Naturally Occurring Autoantibodies...........167
Anti-Fas and Anti-Siglec Naturally Occurring Autoantibodies
in Intravenous Immunoglobulin: Clinical Implications...............................................168
Conclusion................................................................................................................................168
SECTION III: NAbs CAN INDUCE DISEASES
WHEN COMPARTMENT BORDERS BREAK
OR PROTEASES DEGRADE IgG
13. NATURALLY OCCURRING AUTOANTIBODIES MEDIATE
ISCHEMIA/REPERFUSION-INDUCED TISSUE INJURY...................174
Sherry D. Fleming
Abstract.....................................................................................................................................174
Introduction..............................................................................................................................174
Ischemia/Reperfusion-Induced Tissue Damage and Inflammation....................................175
Naturally Occurring Antibodies and Ischemia/Reperfusion...............................................175
Antigens Recognized by NAbs in Rodent Models of IR.......................................................176
Nonmuscle Myosin Type IIA and C and Glycogen Phosphorylase....................................176
NAb Recognition of Annexin IV.............................................................................................177
Anti-Phospholipid and Beta 2 Glycoprotein I Recognition by Antibodies.........................177
Other Possible Antigens and NAb Antigen Summary..........................................................178
Complement Activation in Response to NAb Binding to Tissue..........................................179
Mechanism of Complement Activation by NAbs..................................................................180
Multiple Human NAbs in IVIG Appear Protective..............................................................181
Conclusion and Future Directions..........................................................................................182
14. HOW IMMUNE COMPLEXES FROM CERTAIN IgG NAbs
AND ANY F(ab )2 CAN MEDIATE EXCESSIVE
COMPLEMENT ACTIVATION.................................................................186
Hans U. Lutz
Abstract.....................................................................................................................................186
Introduction..............................................................................................................................186
Stimulation of Complement Amplification by C3b2-IgG Containing
Immune Complexes.........................................................................................................187
Anti-Hinge NAbs Rigidify F(ab )2-IC to Capture Dimeric C3b
and to Stimulate Complement Amplification................................................................189
F(ab )2-Containing Immune Complexes Form Secondary IC with Anti-Hinge
NAbs in Plasma of Septic Patients..................................................................................191
How to Prevent F(ab 2-IC from Stimulating
Complement Amplification?...........................................................................................192
Conclusion................................................................................................................................194
SECTION IV: UNIQUE PROPERTIES OF NAbs
15. THE NATURAL AUTOANTIBODY REPERTOIRE
IN NEWBORNS AND ADULTS: A CURRENT OVERVIEW.................198
Asaf Madi, Sharron Bransburg-Zabary, Dror Y. Kenett, Eshel Ben-Jacob
and Irun R. Cohen
Abstract.....................................................................................................................................198
Introduction..............................................................................................................................199
The Maternal and Newborn Autoantibody Repertoires......................................................200
Antigen-Reactivity Correlations.............................................................................................202
Modular Organization and Antigen Cliques.........................................................................203
Immune Network Architecture and Immune Trees..............................................................204
Antigen Dependency Networks and Influential Antigen-Reactivities.................................205
Discussion..................................................................................................................................208
Conclusion................................................................................................................................210
16. ANTIBODY POLYSPECIFICITY: WHAT DOES IT MATTER?................213
Jordan D. Dimitrov, Anastas D. Pashov and Tchavdar L. Vassilev
Abstract.....................................................................................................................................213
Introduction......................................................................................................................-----213
Biophysical Mechanisms of Polyspecific Antigen Binding...................................................214
Biological Functions of Polyspecific Antibodies...______.__.........--------......—..___......... 216
Induced Polyspecificity—Posttranslational Tuning of Antigen-Binding............................218
In Vivo Induction of Antibody Polyspecificity—the Role of ROS.......................................221
Therapeutic Potential of Antibodies with Induced Polyspecificity......................................222
Conclusion................................................................................................................................223
17. POSITIVE AND NEGATIVE SELECTION OF NATURAL
AUTOREACTIVE B CELLS......................................................................227
Richard R. Hardy and Kyoko Hayakawa
Abstract.....................................................................................................................................227
Introduction..............................................................................................................................228
A Naturally Occurring Autoantibody Specific for Thymocytes...........................................228
ATA-u. Transgenic Mice: Evidence for B-Cell Positive Selection........................................229
ATA-UK Transgenic Mice: Evidence for B-Cell Negative Selection.....................................231
Altering ATA BCR Crosslinking: Marginal Zone B-Cell Development.............................233
Developmental Changes in Natural Autoantibody B-Cell Selection...................................234
Importance of Specificity of Natural Autoantibodies...........................................................236
Conclusion................................................................................................................................236
CONTENTS xxi
18. NATURALLY OCCURRING ANTIBODIES/AUTOANTIBODIES
IN POLYCLONAL IMMUNOGLOBULIN CONCENTRATES.............239
Peter J. Späth and Hans U. Lutz
Abstract.....................................................................................................................................239
Introduction..............................................................................................................................239
NAbs in Immunoglobulin Concentrates: Historical Aspect of the Detection
of Their Therapeutic Use.................................................................................................240
The Origin of NAbs and Their Fractionation
into Immunoglobulin Concentrates................................................................................244
Conclusion................................................................................................................................250
Addendum................................................................................................................................251
INDEX........................................................................................................................263
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV040290715 |
| ctrlnum | (OCoLC)795954231 (DE-599)GBV685351335 |
| dewey-full | 616.07/98 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.07/98 |
| dewey-search | 616.07/98 |
| dewey-sort | 3616.07 298 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01249nam a2200325 cb4500</leader><controlfield tag="001">BV040290715</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">120704s2012 ad|| |||| 00||| eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a">2012005554</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461434603</subfield><subfield code="9">978-1-461-43460-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)795954231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV685351335</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.07/98</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Naturally occurring antibodies (NAbs)</subfield><subfield code="c">ed. by Hans U. Lutz</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer [u.a.]</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 267 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">750</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lutz, Hans Ulrich</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Advances in experimental medicine and biology</subfield><subfield code="v">750</subfield><subfield code="w">(DE-604)BV000003102</subfield><subfield code="9">750</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025145906&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025145906</subfield></datafield></record></collection> |
| id | DE-604.BV040290715 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:20:54Z |
| institution | BVB |
| isbn | 9781461434603 |
| language | English |
| lccn | 2012005554 |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025145906 |
| oclc_num | 795954231 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XXI, 267 S. Ill., graph. Darst. |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Springer [u.a.] |
| record_format | marc |
| series | Advances in experimental medicine and biology |
| series2 | Advances in experimental medicine and biology |
| spelling | Naturally occurring antibodies (NAbs) ed. by Hans U. Lutz New York, NY Springer [u.a.] 2012 XXI, 267 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Advances in experimental medicine and biology 750 Includes bibliographical references and index Lutz, Hans Ulrich Sonstige oth Advances in experimental medicine and biology 750 (DE-604)BV000003102 750 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025145906&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Naturally occurring antibodies (NAbs) Advances in experimental medicine and biology |
| title | Naturally occurring antibodies (NAbs) |
| title_auth | Naturally occurring antibodies (NAbs) |
| title_exact_search | Naturally occurring antibodies (NAbs) |
| title_full | Naturally occurring antibodies (NAbs) ed. by Hans U. Lutz |
| title_fullStr | Naturally occurring antibodies (NAbs) ed. by Hans U. Lutz |
| title_full_unstemmed | Naturally occurring antibodies (NAbs) ed. by Hans U. Lutz |
| title_short | Naturally occurring antibodies (NAbs) |
| title_sort | naturally occurring antibodies nabs |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025145906&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003102 |
| work_keys_str_mv | AT lutzhansulrich naturallyoccurringantibodiesnabs |